BB
GEVA

BB Biotech’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BB Biotech’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,025,476
Closed -$100M – 31
2015
Q1 		$100M Sell
1,025,476
-105,000
-9% -$11.1M 2.98% 13
2014
Q4 		$105M Buy
1,130,476
+37,000
+3% +$2.92M 3.4% 10
2014
Q3 		$75.2M Buy
1,093,476
+195,000
+22% +$14M 3.06% 12
2014
Q2 		$94.2M Sell
898,476
-41,481
-4% -$3.53M 4.47% 8
2014
Q1 		$78M Buy
939,957
+81,200
+9% +$7.51M 4.02% 8
2013
Q4 		$55.6M Buy
858,757
+144,155
+20% +$8.56M 2.97% 10
2013
Q3 		$45.3M Buy
714,602
+661,053
+1,234% +$32.5M 2.46% 12
2013
Q2 		$2.25M Buy
+53,549
New +$2.44M 0.16% 23

BB Biotech's GEVA Position: Q2 2015 in Review

BB Biotech sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,025,476 shares — an estimated $100M sold.

BB Biotech first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $105M in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BB Biotech reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BB Biotech sold 1,025,476 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $100M.
  • BB Biotech first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BB Biotech's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $105M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BB Biotech's 13F filing for Q2 2015, filed 12 Aug 2015.